This draft Statutory Instrument supersedes the draft of the same title which was laid before Parliament on 16th January 2012 and published on 19th January 2012 (ISBN 978-0-11-151926-4). It is being issued free of charge to all known recipients of that draft Statutory Instrument.
Draft Order laid before Parliament under section 2(5) of the Misuse of Drugs Act 1971 for approval by resolution of each House of Parliament.
2012 No.
Dangerous Drugs
The Misuse of Drugs Act 1971 (Amendment) Order 2012
Made
Coming into force in accordance with article 1

At the Court at Buckingham Palace, the day of 2012
Present,
The Queen’s Most Excellent Majesty in Council
In accordance with section 2(5) of the Misuse of Drugs Act 1971 a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.
1971 c. 38. Schedule 2 has been amended by section 21 of the Drugs Act 2005 (c. 17) and S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589, 1995/1966, 1996/1300, 1998/750, 2001/3932, 2003/1243, 2003/3201, 2005/3178, 2006/3331, 2008/3130, 2009/3209, 2010/1207, 2010/1833 and 2011/744.
Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:

1 Citation, commencement and interpretation
1 This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2012 and shall come into force on the fourteenth day after the day on which it is made.
2 In this Order “the 1971 Act” means the Misuse of Drugs Act 1971.

Amendments to the 1971 Act
2 In Part 2 of Schedule 2 to the 1971 Act (which specifies the drugs which are subject to control under that Act as Class B drugs)—
(a) after paragraph 1(ab), insert—

“(ac) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,
(i) i)by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;
(ii) by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;
(iii) by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.”

;
(b) in paragraph 2A, for “paragraph 1(c)” substitute “paragraph 1(ac) or (c)”.
3 In Part 3 of Schedule 2 to the 1971 Act (which specifies the drugs which are subject to control under that Act as Class C drugs)—
(a) in paragraph 1(a)—
(i) omit “Pipradrol”; and
(ii) after “Bromazepam”, insert—

“7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one.”

; and
(b) in paragraph 1(b), after “Oxymetholone.”, insert—

“Pipradrol.”

.
Clerk of the Privy Council

EXPLANATORY NOTE
(This note is not part of the Order)
This Order adds, in article 2, Desoxypipradrol and other Pipradrol‑related compounds to Part 2 of Schedule 2 to the Misuse of Drugs Act 1971 (the “1971 Act”) which specifies drugs which are subject to control as Class B drugs under that Act. Article 3(a) omits Pipradrol from, and adds 7‑bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (commonly known as Phenazepam) to, paragraph 1(a) of Part 3 of Schedule 2 to the 1971 Act which specifies drugs which are subject to control as Class C drugs under that Act. Article 3(b) adds Pipradrol to paragraph 1(b) of Part 3 of Schedule 2 to the 1971 Act.